Literature DB >> 32410113

Flexible multidentate benzyldiamine derivatives with high affinity for β-amyloid in cerebral amyloid angiopathy.

Yujia He1, Tingting Fu2, Yuying Li3, Weiwei Xue4, Mengchao Cui3, Liang Wang1, Mengda Niu1, Zhiping Peng5, Jianhua Jia6.   

Abstract

Cerebral amyloid angiopathy (CAA) commonly found in the aged is pathologically characterized by β-amyloid (Aβ) deposition in the walls of arteries and capillaries of brain. In this study, four flexible multidentate benzyldiamine derivatives as potential probes for cerebrovascular Aβ deposition were designed and synthesized. In in vitro inhibition assays, the ligands 18-21 displayed high affinities for Aβ aggregates with Ki values of 1.45 ± 0.53 nM, 1.68 ± 0.35 nM, 1.16 ± 0.23 nM and 1.72 ± 0.19 nM, respectively. A significant improvement in the binding affinity over the monomer, compounds 9-12 or benzyldiamine derivatives, demonstrated the applicability of the multidentate approach. The underlying mechanism of these novel Aβ agents was explored by molecular docking technique, which theoretically verified the high affinities of the multidentate benzyldiamine derivatives for Aβ aggregates. Moreover, the molecular masses of the ligands 18-21 are more than 700 Dalton, which are believed to be hardly capable of penetrating blood brain barrier. In this regard, these ligands could be used to distinguish CAA from Alzheimer's disease which is another Aβ-related disorder disease. To convert these ligands to positron emission tomography imaging agents, we attempted to radiosynthesize [18F]18. Though the radiolabeling was not very successful, the preliminary results suggested that these newly proposed multidentate benzyldiamine derivatives may be used as potential Aβ imaging agents in cerebral amyloid angiopathy.

Entities:  

Keywords:  Affinity; Cerebral amyloid angiopathy; Molecular docking; Radiolabeling; β-Amyloid

Year:  2020        PMID: 32410113     DOI: 10.1007/s11030-020-10098-y

Source DB:  PubMed          Journal:  Mol Divers        ISSN: 1381-1991            Impact factor:   2.943


  22 in total

1.  Imaging of amyloid burden and distribution in cerebral amyloid angiopathy.

Authors:  Keith A Johnson; Matt Gregas; John A Becker; Catherine Kinnecom; David H Salat; Erin K Moran; Erin E Smith; Jonathan Rosand; Dorene M Rentz; William E Klunk; Chester A Mathis; Julie C Price; Steven T Dekosky; Alan J Fischman; Steven M Greenberg
Journal:  Ann Neurol       Date:  2007-09       Impact factor: 10.422

2.  Cerebral hemorrhage in amyloid angiopathy.

Authors:  K Jellinger
Journal:  Ann Neurol       Date:  1977-06       Impact factor: 10.422

Review 3.  Cerebral amyloid angiopathy in East and West.

Authors:  Yu-Wei Chen; Ming-Jen Lee; Eric E Smith
Journal:  Int J Stroke       Date:  2010-10       Impact factor: 5.266

Review 4.  Review: sporadic cerebral amyloid angiopathy.

Authors:  J Attems; K Jellinger; D R Thal; W Van Nostrand
Journal:  Neuropathol Appl Neurobiol       Date:  2011-02       Impact factor: 8.090

5.  Pittsburgh compound B binding in poststroke dementia.

Authors:  Vincent Mok; Eric Yim Lung Leung; Winnie Chu; Sirong Chen; Adrian Wong; Yunyun Xiong; Wynnie Lam; Chi Lai Ho; Ka Sing Wong
Journal:  J Neurol Sci       Date:  2010-01-06       Impact factor: 3.181

6.  Whole-body biodistribution and radiation dosimetry of 18F-GE067: a radioligand for in vivo brain amyloid imaging.

Authors:  Michel Koole; Dewi M Lewis; Christopher Buckley; Natalie Nelissen; Mathieu Vandenbulcke; David J Brooks; Rik Vandenberghe; Koen Van Laere
Journal:  J Nucl Med       Date:  2009-04-16       Impact factor: 10.057

Review 7.  Genetics and molecular pathogenesis of sporadic and hereditary cerebral amyloid angiopathies.

Authors:  Tamas Revesz; Janice L Holton; Tammaryn Lashley; Gordon Plant; Blas Frangione; Agueda Rostagno; Jorge Ghiso
Journal:  Acta Neuropathol       Date:  2009-02-19       Impact factor: 17.088

8.  Imaging of amyloid beta in Alzheimer's disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism.

Authors:  Christopher C Rowe; Uwe Ackerman; William Browne; Rachel Mulligan; Kerryn L Pike; Graeme O'Keefe; Henry Tochon-Danguy; Gordon Chan; Salvatore U Berlangieri; Gareth Jones; Kerryn L Dickinson-Rowe; Hank P Kung; Wei Zhang; Mei Ping Kung; Daniel Skovronsky; Thomas Dyrks; Gerhard Holl; Sabine Krause; Matthias Friebe; Lutz Lehman; Stefanie Lindemann; Ludger M Dinkelborg; Colin L Masters; Victor L Villemagne
Journal:  Lancet Neurol       Date:  2008-01-10       Impact factor: 44.182

9.  Detection of isolated cerebrovascular beta-amyloid with Pittsburgh compound B.

Authors:  Steven M Greenberg; Thomas Grabowski; M Edip Gurol; Maureen E Skehan; R N Kaveer Nandigam; John A Becker; Monica Garcia-Alloza; Claudia Prada; Matthew P Frosch; Jonathan Rosand; Anand Viswanathan; Eric E Smith; Keith A Johnson
Journal:  Ann Neurol       Date:  2008-11       Impact factor: 10.422

10.  Using PET with 18F-AV-45 (florbetapir) to quantify brain amyloid load in a clinical environment.

Authors:  V Camus; P Payoux; L Barré; B Desgranges; T Voisin; C Tauber; R La Joie; M Tafani; C Hommet; G Chételat; K Mondon; V de La Sayette; J P Cottier; E Beaufils; M J Ribeiro; V Gissot; E Vierron; J Vercouillie; B Vellas; F Eustache; D Guilloteau
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-01-18       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.